| First Author | Yang R | Year | 2023 |
| Journal | Int Immunopharmacol | Volume | 124 |
| Issue | Pt A | Pages | 110865 |
| PubMed ID | 37660596 | Mgi Jnum | J:340599 |
| Mgi Id | MGI:7528478 | Doi | 10.1016/j.intimp.2023.110865 |
| Citation | Yang R, et al. (2023) Tespa1 deficiency reduces the antitumour immune response by decreasing CD8(+)T cell activity in a mouse Lewis lung cancer model. Int Immunopharmacol 124(Pt A):110865 |
| abstractText | Thymocyte-expressed, positive selection-associated 1 (Tespa1) is a key molecule in T-cell development and has been linked to immune diseases. However, its role in antitumour CD8(+)T cell immunity remains unclear. Here, we demonstrated that Tespa1 plays an important role in antitumour CD8(+)T cell immunity. First, compared with wild-type (WT) mice, Lewis lung cancer cells grew faster in Tespa1 knockout (Tespa1(-/-)) mice, with reduced apoptosis, and decreased CD8(+)T cells in peripheral blood and tumor tissues. Second, the proportion of CD8(+)T and Th1 cells in the splenocytes of Tespa1(-)(/)(-) mice was lower than that in WT mice. Third, Tespa1(-)(/)(-) CD8(+) tumor-infiltrating lymphocytes (TILs) showed weakened proliferation, invasion, cytotoxicity, and protein expression of IL-2 signalling pathway components compared to WT CD8(+)TILs. Furthermore, PD-1 expression in CD8(+)TILs was higher in Tespa1(-/-) than in WT mice. Lastly, CD8(+)TILs in WT mice improved the antitumour ability of Tespa1(-/-) mice. In conclusion, these findings suggest that Tespa1 plays a critical role in the tumor immune system by regulating CD8(+)T cells. |
